GNH USA

Europe — EMA

Mirabegron Glenmark

GNH USA supplies Mirabegron Glenmark (Mirabegron), an adrenergic agonist for overactive bladder, urgency and urge incontinence. Request a quote for supply.

Mirabegron

Request sourcing

1
Pack/s

What is Mirabegron?

Mirabegron, the active ingredient in Mirabegron Glenmark, is a beta-3 adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge urinary incontinence in adults.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Mirabegron used for?

Mirabegron is indicated for conditions within the overactive bladder disease family.

- Overactive bladder: reduces urinary urgency and frequency, improving bladder capacity. - Urinary urgency: lessens the sudden strong urge to void. - Urge urinary incontinence: decreases episodes of involuntary leakage.

What are the side effects of Mirabegron?

Common Side Effects: - Hypertension - Nasopharyngitis - Urinary tract infection - Headache - Constipation - Dry mouth

Serious or Rare Side Effects: - Urinary retention - Tachycardia - Angioedema - Severe hypertension - Allergic reactions (including rash, pruritus) - Myocardial infarction

What precautions apply to Mirabegron?

Precautions should be observed before initiating therapy.

- Assess cardiovascular status: monitor blood pressure before and during treatment. - Review renal function: dose may need adjustment in severe impairment. - Avoid use in uncontrolled hypertension: contraindicated. - Caution in hepatic impairment: monitor liver enzymes regularly. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

What does Mirabegron interact with?

Potential drug interactions require careful assessment.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron exposure. - Antihypertensive agents: additive blood‑pressure‑lowering effect. - Norepinephrine reuptake inhibitors: risk of increased hypertension. - Diuretics: may reduce mirabegron efficacy.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish therapeutic benefit. - Other β3‑adrenergic agonists: potential additive bladder effects. - Warfarin: monitor INR as mirabegron can affect metabolism.

Frequently asked questions

What is Mirabegron Glenmark used for?+
Mirabegron Glenmark is prescribed to manage symptoms of overactive bladder, including urinary urgency, frequency, and urge urinary incontinence. It helps increase bladder capacity and reduce involuntary contractions, improving daily comfort for patients with these conditions.
How does Mirabegron work in the body?+
The drug activates β3‑adrenergic receptors in the bladder’s detrusor muscle. This activation relaxes the smooth muscle, allowing the bladder to hold a larger volume of urine and decreasing the frequency of unwanted contractions that cause urgency and leakage.
What is the usual dose of Mirabegron Glenmark?+
The appropriate dose is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Mirabegron safe during pregnancy or breastfeeding?+
Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.
How do I order Mirabegron Glenmark from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Mirabegron compare with anticholinergic bladder drugs?+
Mirabegron belongs to a different class (β3‑adrenergic agonist) and does not have the anticholinergic side‑effects such as dry mouth or constipation that are common with anticholinergic agents. It may be chosen when patients cannot tolerate anticholinergics or when a different mechanism of action is desired.
What are the storage requirements for Mirabegron Glenmark?+
Store the tablets at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.
How is Mirabegron Glenmark administered?+
Mirabegron Glenmark is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed.
What are the most serious risks associated with Mirabegron?+
Serious risks include significant hypertension, urinary retention, tachycardia, angioedema and rare cardiac events such as myocardial infarction. Patients should be monitored for these conditions, especially if they have pre‑existing cardiovascular disease.
Who should not use Mirabegron Glenmark?+
Mirabegron is contraindicated in patients with uncontrolled hypertension and should be used with caution in those with severe renal or hepatic impairment. Individuals who have experienced severe allergic reactions to mirabegron or any of its excipients should also avoid the medication.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mirabegron
Route
Oral Use
Manufacturer
Glenmark Arzneimittel Gmbh
Origin
EU

Related products

Myrbetriq 25 mg/1

Myrbetriq 25 mg/1

Mirabegron · 25 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA
Myrbetriq 25 mg/1

Myrbetriq 25 mg/1

Mirabegron · 25 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA
Myrbetriq 25 mg/1

Myrbetriq 25 mg/1

Mirabegron · 25 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA
Myrbetriq 50 mg/1

Myrbetriq 50 mg/1

Mirabegron · 50 mg

Myrbetriq
TABLET, FILM COATED, EXTENDED RELEASE
Astellas Pharma US, Inc.
USA